SCHEMBL441959

SCHEMBL441959

O=C(O)N1CC(COCc2ccccc2)C(O)C(OCc2ccccc2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42
AGTR2 P50052 3/20 0.41
PDE4D Q08499 1/20 0.40
ATM Q13315 1/20 0.38
CTSL P07711 2/20 0.38
CTSB P07858 2/20 0.38
CTSK P43235 2/20 0.38
CTSV O60911 1/20 0.38
CTSS P25774 1/20 0.38
CTSC P53634 1/20 0.38
CTSF Q9UBX1 1/20 0.38
GRM5 P41594 1/20 0.37
NR1D1 P20393 1/20 0.36
ABHD6 Q9BV23 3/20 0.36
DAGLA Q9Y4D2 2/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5465296 0.89 SMN1; SMN2 (0.46) BCHEACHEAGTR2
SCHEMBL439043 0.87 GBA1 (0.44) BCHEPDE4DCTSLCTSBCTSK
SCHEMBL13090653 0.81 GBA1 (0.49) BCHEACHEPDE4D
SCHEMBL2456870 0.81 SMN1; SMN2 (0.40) BCHECTSLCTSBCTSKCTSV
SCHEMBL18040923 0.80 BCHE (0.43) BCHEPDE4DCTSLCTSBCTSK
SCHEMBL2914271 0.79 BCHE (0.43) BCHEACHEAGTR2PDE4DATM
SCHEMBL21855171 0.77 AGTR2 (0.51) AGTR2CTSLCTSBCTSKGRM5
SCHEMBL5447024 0.77 SMN1; SMN2 (0.48)
SCHEMBL21196194 0.76 CTSL (0.40) BCHEACHEAGTR2CTSLCTSB
SCHEMBL30379975 0.76 CTSL (0.40) BCHEACHEAGTR2CTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065153-A1 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF SANOFI-AVENTIS (FR) 2012-03-15 US disclosed
EP-1773854-B1 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF SANOFI SA (FR) 2011-09-21 EP disclosed
EP-1773854-A2 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF Sanofi-Aventis (FR) 2007-04-18 EP disclosed
WO-2006021653-A2 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF SANOFI-AVENTIS (FR) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065153-A1 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF HPSE, HAAO, HEXD BCHE 1419/4885ACHE 1091/4885AGTR2 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.